ArticleClinical and experimental medicine2023

Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.

Matteo Santoni et al.PubMed ↗Publisher ↗

No numbers read from the abstract.